Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: Improved outcome with intensified induction treatment [6]

Leukemia

Volumn 19, Issue 8, 2005, Pages 1495-1496

  Reinhardt, Dirk ^a,g   Diekamp, S ^b   Langebrake, C ^b   Ritter, J ^b   Stary, J ^b   Dworzak, M ^c   Schrauder, A ^d   Zimmermann, M ^d   Fleischhack, G ^b   Ludwig, W D ^e   Harbott, J ^f   Greutzig, U ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^d CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY HOSPITAL GIESSEN   (Germany)

^g Section of Pathology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CD61 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; MITOXANTRONE;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CAUSE OF DEATH; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 19; CHROMOSOME 3Q; CHROMOSOME 5Q; CHROMOSOME 7Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME ARM; CHROMOSOME LOSS; CLINICAL FEATURE; CYTOGENETICS; DOWN SYNDROME; FEMALE; GRAFT REJECTION; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOLOGY; KARYOTYPE; LETTER; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TRISOMY; WHOLE BODY RADIATION;

EID: 23744514778     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403815     Document Type: Letter

References (9)

1. Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia - Berlin - Frankfurt - Munster 93. J Clin Oncol 2001; 19: 2705-2713.
2. Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004; 22: 4384-4393.
3. Athale UH, Razzouk BI, Raimondi SC, Tong X, Behm FG, Head DR et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood 2001; 97: 3727-3732.
4. Hann IM, Webb DK, Gibson BE, Harrison CJ. MRC trials in childhood acute myeloid leukaemia. Ann Hematol 2004; 83 (Suppl 1): S108-S112.
5. Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 1998; 101: 130-140.
6. Dastugue N, Lafage-Pochitaloff M, Pages MP, Radford I, Bastard C, Talmant P et al. Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Francais de Cytogenetique Hematologique (GFCH). Blood 2002; 100: 618-626.
7. Duchayne E, Fenneteau O, Pages MP, Sainty D, Arnoulet C, Dastugue N et al. Acute megakaryoblastic leukaemia: a national clinical and biological study of 53 adult and childhood cases by the Groupe Francais d'Hematologie Cellulaire (GFHC). Leuk Lymphoma 2003; 44: 49-58.
8. Garderet L, Labopin M, Gorin NC, Polge E, Baruchel A, Meloni G et al. Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Blood 2005; 105: 405-409.
9. Krance RA, Hurwitz CA, Head DR, Raimondi SC, Behm FG, Crews KR et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol 2001; 19: 2804-2811.